Table 2 Clinical trials on piperine*
Condition & (number of patients) | Phases I, II, III or IV & (Status) | Dose, duration | Principal Investigator affiliation | Duration (months) | References |
|---|---|---|---|---|---|
KOA (60) | I (Completed) | 7.5 mg/day, 4 wks | Motahar Heidari-Beni, IUMS | Jan 2018–May 2018 (5) | Heidari-Beni et al. [154] |
TCS 12) | I (Completed) | 20 mg/day,10 days | S. K. Bedada, UCPSKU | 2016–2016 – | |
MS (12) | I (Completed) | 20 mg/day, 2 days | HMO & A. Hoffman and A. Domb, DRBCPHU | Aug 2013–Jan 2015 (17) | Cherniakov et al. [157] |
AIDS (08) | I (Completed) | 20 mg/day,7 days | Ravisekhar Kasibhatta, BCRPL, Hyderabad | 2007–2008 – | Kasibhatta and Naidu [158] |
NAFLD (79) | III (Completed) | 5 mg/day, 8 weeks | Dr. Abasalt Borji, NUMS | Jan 2017–Nov 2017 (10) | Mirhafez et al. [159] |
T2DM (100) | III (Ongoing) | 5 mg/day, 12weeks | Jun 2015–Present (12) | * | |
NAFLD (70) | II (Ongoing) | 5 mg/day, 12weeks | Jan 2018–Present – | ||
HIVS (60) | I (Completed) | – | Philip C Smith, School of Pharmacy, UNC Chapel Hill | Sep 2003–Mar 2006 (30) | |
MN, Pain, BS, Urinary Urgency (09) | I (Active, not recruiting) | – | Aminah Jatoi, Mayo Clinic, Rochester, Minnesota, United States | Mar 2016–Mar 2021 (60) | |
CKD (30) | NA (Recruiting) | 500 mg of curcumin and piperine, 3 capsules/day, 12 weeks | Denise Mafra, Federal University Fluminense, Rio de Janeiro, Brazil | Oct 2020–Oct 2021 (12) | |
Hair Thinning (70) | NA Recruiting) | 95% piperine extract in formulation, 4 capsules/ day, 180 days | Glynis Ablon, ABSIRC, Manhattan Beach, California, United States | Jun 2019–Jan 2021 (18) | |
Epilepsy (10) | I (Completed) | 20 mg/day, 2 days | Smita Pattanaik, NOD-PGIMER, Chandigarh, India | 2017–2017 – | Pattanaik et al. [160] |
OD (40) | I&II (Completed) | Group1 = 150 μM Group 2 = 1 mM | Laia Rofes, GPLRU, Hospital de Mataro´, Spain | Jun 2011–Feb 2012 (9) | Rofes et al. [161] |
MS (12) | I (Completed) | 20 mg/day, 10 days | S K Bedada, UCPSKU | 2016–2016 – | Bedada and Boga [162] |
OA (53) | III (Completed) | 15 mg/day, 6 weeks | Dr. Yunes Panahi, CIRC-BUC, CRDU-BH, BUMS, Iran | Jan 2011–Jan 2012 (12) | |
Vitiligo (63) | II&III (Completed) | 1% Topical solution, 12weeks | Anoosh Shafiee, SRC-SBUM, Iran | Jun 2016–Sep 2016 (3) | Shafiee et al. [15] |